Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Simon Lord"'
Autor:
N. P. Scott, D. D. Remoundos, Pankaj G. Roy, Fergus V. Gleeson, H Flight, Cheng Liu, Simon Lord, Daniel R. McGowan, L. Mustata, J. Niederer, G. M. MacLean, Cameron Snell, A L Harris, B. E. Jones, Eugene Teoh
Publikováno v:
British Journal of Cancer. 126:598-605
Background 18F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of 18F-fluciclovin
Autor:
Gary S. Collins, Stavros Petrou, Ash Kieran Clift, Julia Hippisley-Cox, Sir Michael Brady, David Dodwell, Simon Lord
Publikováno v:
British Journal of Cancer. 126:533-550
Apart from high-risk scenarios such as the presence of highly penetrant genetic mutations, breast screening typically comprises mammography or tomosynthesis strategies defined by age. However, age-based screening ignores the range of breast cancer ri
Autor:
Simon Lord, Farasat Kazmi, Francesca Aroldi, Stephen Booth, Nipun Shrestha, Kheng-Wei Yeoh, Brian D Nicholson, Sarah P. Blagden, David Dodwell, Philip Heesen, Thomas Foord
Publikováno v:
Cochrane Database of Systematic Reviews
Cochrane Database Syst Rev
Cochrane Database Syst Rev
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the effectiveness and safety of matched targeted therapies in people with relapsed or metastatic cancer in phase I, II and III trials.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef1c1cc3877e47645dd96db84b73047c
https://ora.ox.ac.uk/objects/uuid:4f6905c7-8019-47df-874c-1ac469692738
https://ora.ox.ac.uk/objects/uuid:4f6905c7-8019-47df-874c-1ac469692738
Autor:
Simon Lord, Francesca Aroldi
Publikováno v:
British Journal of Cancer
Window of opportunity trials exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy. In recent years this study design has become a more regular feature of drug development, as this ‘window’ provi
Autor:
Sahirzeeshan Ali, E. Ainscow, Ash Bahl, Sagar Sardesai, Janine Mansi, H-T. Arkenau, M. Lehnert, P. Richards, Simon Lord, S. McIntosh, Glen Clack, R. C. Coombes, Sacha J Howell, Laura M. Kenny, Z. Mitri, Rinath Jeselsohn, Joyce O'Shaughnessy, Matthew G Krebs, Carlo Palmieri, William J. Gradishar
Publikováno v:
Annals of Oncology. 32:S477-S478
Autor:
Hannah M. Linden, Simon Lord, S. Cartot-Cotton, Vasiliki Pelekanou, A. Gosselin, M. Campone, Sarat Chandarlapaty, Patrick Neven, Aditya Bardia, Valentina Boni, Peter Kabos, Marina Celanovic
Publikováno v:
Annals of Oncology. 32:S511-S512
Autor:
Analia Azaro, Jordi Rodon, Constanza Linossi, Richard D. Baird, Ulrike Fiedler, Simon Lord, Keith M. Dawson, Aurelius Omlin, Nicolas Leupin, Andreas Harstrick, Stefanie Fischer, Michael T. Stumpp, Christof Zitt, Mark R. Middleton, Adrian L. Harris
Publikováno v:
Journal of Clinical Oncology
PURPOSE A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disrupting the tumor microenvironment. P
Autor:
John Pollard, Robert Wesolowski, Bart S. Hendriks, Craig Devoe, Martin H. Falk, Timothy A. Yap, Geoffrey I. Shapiro, Simon Lord, Ivan Diaz-Padilla, Ruth Plummer
Publikováno v:
British Journal of Cancer
BackgroundBerzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary eff
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 20(12)
Autor:
Mark R. Middleton, P S Virdee, Leena Elhussein, Martin Eatock, M Goff, Sharon Love, Anne Thomas, Stephen Falk, Joanna Moschandreas, Richard C. Turkington, D. Alan Anthoney, L Collins, Simon Lord
Publikováno v:
Thomas, A, Virdee, P S, Eatock, M, Lord, S R, Falk, S, Anthoney, D A, Turkington, R C, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J & Middleton, M R 2020, ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ', European Journal of Cancer, vol. 124, pp. 131-141 . https://doi.org/10.1016/j.ejca.2019.10.010
European Journal of Cancer
European Journal of Cancer
Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3f4d7b04b1b1073ec0ebfa84b2946
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897